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ABSTRACT
Introduction: The rate of unplanned pregnancy in
Australia remains high, which has contributed to
Australia having one of the highest abortion rates of
developed countries with an estimated 1 in 5
women having an abortion. The emergency
contraceptive pill (ECP) offers a safe way of
preventing unintended pregnancy after unprotected
sex has occurred. While the ECP has been available
over-the-counter in Australian pharmacies for over a
decade, its use has not significantly increased. This
paper presents a protocol for a qualitative study that
aims to identify the barriers and facilitators to
accessing the ECP from community pharmacies in
Australia.
Methods and analysis: Data will be collected
through one-on-one interviews that are
semistructured and in-depth. Partnerships have
been established with 2 pharmacy groups and 2
women’s health organisations to aid with the
recruitment of women and pharmacists for data
collection purposes. Interview questions explore
domains from the Theoretical Domains Framework
in order to assess the factors aiding and/or
hindering access to ECP from community
pharmacies. Data collected will be analysed using
deductive content analysis. The expected benefits of
this study are that it will help develop evidence-
based workforce interventions to strengthen the
capacity and performance of community
pharmacists as key ECP providers.
Ethics and dissemination: The findings will be
disseminated to the research team and study
partners, who will brainstorm ideas for interventions
that would address barriers and facilitators to
access identified from the interviews. Dissemination
will also occur through presentations and peer-
reviewed publications and the study participants will
receive an executive summary of the findings. The
study has been evaluated and approved by the
Monash Human Research Ethics Committee.
INTRODUCTION
The rate of unplanned pregnancy in
Australia remains high and nearly half of all
Australian women of reproductive age have
experienced an unplanned pregnancy.1
Australia is reported to have one of the
highest abortion rates of developed countries
with an estimated one in ﬁve women having
an abortion.2 The emergency contraceptive
pill (ECP) offers a way of preventing unin-
tended pregnancy after unprotected sex has
occurred. It is important to note that many
of the previous randomised controlled
trials3–6 demonstrating no association
between ECP access or its advanced provision
and unintended pregnancy or abortion rates
have mostly been conducted in postpartum
or family management clinics or hospitals,
and thus targeted women who were already
accessing specialised forms of care. However,
one trial has demonstrated that increasing
access to the ECP can reduce unintended
Strengths and limitations of this study
▪ Contribution of new knowledge to the limited lit-
erature on barriers to emergency contraceptive
pill access in the Australian context that will help
inform the development and implementation of
interventions in community pharmacy to
enhance access.
▪ Use of the Theoretical Domains Framework that
includes constructs from 33 behaviour change
theories, to conduct and analyse the interviews
and ultimately inform the interventions.
▪ Recruitment challenge is an anticipated problem
due to the sensitive nature of the research topic
and the fear of disclosure or privacy concerns,
potentially delaying the study timeline.
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pregnancy rates during breast feeding,7 highlighting the
importance of the culture, setting and context of such
trials. Women in general health settings such as commu-
nity pharmacy may have different attitudes, needs and
health-seeking behaviours, and the care they receive
may not be as systematic or evidence-based. Further, rela-
tionships between women and community pharmacists,
and women and general practitioners (GPs), may also
be different, with pharmacy being challenged by the
consumer’s power in the commercial transaction and
perceived expertise in the management of minor illness.
It is therefore critical to study these populations in
greater depth than what has already been investigated,4 8
that is, in several countries and different cultural con-
texts, to determine an effect of enhanced ECP access on
unintended pregnancy rates.
While the ECP is safe and has no medical contraindi-
cations, there are signiﬁcant barriers to pharmacy access
in Australia and overseas.9 Barriers such as suboptimal
acceptance by healthcare providers and the public, and
multiple ﬁnancial and healthcare system barriers to
use,10 are preventing the ECP’s potential for reducing
unintended pregnancies and abortion rates to be rea-
lised. The only ECP in Australia, containing levonorges-
trel, has been available since 2004 through community
pharmacies as a ‘Pharmacist Only Medicine’ without a
prescription. In Australia, Pharmacist Only Medicines
must be stored in a part of the pharmacy not accessible
to the public and supplied only for a therapeutic need
after the pharmacist has personally taken reasonable
steps to ensure that such a need exists. The
Pharmaceutical Society of Australia (PSA) released the
ﬁrst protocol to guide pharmacists’ supply of the ECP in
200311 and released an updated version in 2006.12 In
2011, the PSA revised the 2006 protocol and released
another updated practice guideline for levonorgestrel
provision that contains the latest scientiﬁc evidence
regarding its use.13 The revisions address several factors
including the time frame that levonorgestrel can be
used within, which was changed to allow use up to 96 h
after intercourse, compared with the product informa-
tion that indicated use within 72 h. The revision also
established that advance supply does not negatively
impact on sexual and reproductive health. Lastly, there
was an acknowledgement that there is limited data
regarding the use of the ECP in females aged 14–
16 years, and the pharmacist needs to refer to a GP
where advisable; however, the guideline highlighted that
there was no reason for ECP use to be restricted on the
basis of age.
Pharmacists’ practices in Australia are variable, com-
monly not meeting evidence-based recommendations in
the PSA guideline and resulting in women being
unnecessarily declined ECP supply.14 15 Women’s experi-
ences of obtaining the ECP from pharmacies are both
positive and negative.9 Some positive experiences
reported by women include faster and more direct
access, convenient location, and feeling of more control
over their reproductive health, while some negative
experiences reported include lack of privacy, judgemen-
tal or indifferent pharmacist attitude, cost of ECP and so
on. Compounding this is the unexplained paradox
between unplanned pregnancy rates and ECP
availability.16
Access to emergency contraception, especially the
ECP, is essential as it helps prevent unwanted pregnan-
cies—an important public health goal. If the ECP is
refused by a pharmacist or GP, women are placed at risk
of having an unwanted pregnancy that may result in an
abortion or be carried to term with long-term implica-
tions for the woman and her partner. This study seeks to
understand the underpinning reasons for refusal of
supply that make access to this medicine unnecessarily
complex.
The ECP was made available over-the-counter (OTC)
in Australia with the view that it would allow women to
access the ECP more quickly than from a GP, and there-
fore lead to a decrease in the unplanned pregnancy rate
in Australia. A focus group study suggested that
Australian women aged 16–30 years were in favour of
pharmacy availability of the ECP, as faster and more
direct access is afforded, particularly on Sundays and for
women living in rural and remote locations.17 However,
a decade later, despite pharmacy availability of the ECP,
it seems that Australian women’s use of the ECP has
neither signiﬁcantly increased nor has the rate of
unplanned pregnancies signiﬁcantly decreased. A study
conducted in Sydney that surveyed 718 women on ECP
use concluded that OTC availability and access to the
ECP increased women’s awareness but did not signiﬁ-
cantly increase ECP use among abortion seekers.18
A research study examining the attitudes and practices
of pharmacists in Australia in relation to their increased
role in ECP provision following the policy change to
OTC availability found that pharmacists’ attitudes and
beliefs play a major role in ECP dispensing.15 Australian
pharmacists had stronger and more conservative views
than overseas pharmacists, and 22% of the pharmacists
surveyed felt it was reasonable for a pharmacist’s reli-
gious faith to inﬂuence ECP supply. This seems stark
compared with the survey response of pharmacists in
Nova Scotia, Canada, where only 1.6% of pharmacists
indicated that they had not provided the ECP due to
moral, religious or ethical objections.19 In addition,
pharmacists’ decision to decline ECP provision in
Australia is because of incorrect beliefs regarding
advance prescription, the responsible use of ECP and its
impact on sexual reproductive health.15 Pharmacists also
noted a number of problems with the number of differ-
ing written protocols used to dispense the ECP. In
another study examining attitudes of pharmacy assistants
in Northern Queensland, 22% of those interviewed felt
it was reasonable for a pharmacists’ religious faith to
inﬂuence ECP supply, while 65% of pharmacists inter-
viewed identiﬁed young age as the most common reason
for refusing to dispense ECP.20
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The ﬁrst random population-based study of Australian
women’s ECP knowledge, attitudes and use since its
availability without a prescription surveyed 632
Australian women aged 16–35 years.9 This study found
that less than half were aware that ECP was available
from pharmacies without a prescription and 57% did
not think they were at risk of getting pregnant. While
most women felt the ECP was effective at preventing
pregnancy, less than half believed that is was safe or very
safe for the health of women. Of the women surveyed,
32% thought that the ECP was an abortifacient, when in
fact, it delays ovulation. In addition, more than half the
women reported feeling somewhat or very uncomfort-
able when asking for the ECP at a pharmacy and less
than half thought it was the role of the pharmacist to
give women advice about contraception and sexually
transmissible infections at the time the ECP is obtained.
Although Australian women have a high awareness of
the ECP, their knowledge about how and when to use it
and where to obtain it is inadequate, thus increasing
their risk of becoming pregnant.9
A comprehensive barriers analysis to determine
pharmacist-related and patient-related barriers to ECP
provision has not been done in Australia or overseas,
although some light has been indirectly thrown onto
this issue in a previous mystery caller study of a sample
of pharmacies in Victoria, Australia.14 In this study, 515
pharmacists were randomly allocated one of three scen-
arios when supplying the ECP and these scenarios exem-
pliﬁed the three major areas of change in the revised
PSA guideline: outside the licensed 72 h time frame
(scenario 1); by a woman under 16 years (scenario 2);
and for future use (scenario 3). These scenarios tested
actual performance in situations for which pharmacists’
self-reported responses in a previous study were inappro-
priate.15 It was found that 55.4% of pharmacists tested
for scenario 1 declined supply and most referred to the
doctor; and 46.1% and 40% denied supply for scenarios
2 and 3, respectively. The study concluded that Victorian
pharmacists’ practices in relation to ECP provision are
not always in line with the recommendations in the PSA
guideline.
These ﬁndings are mirrored by a recent review of
workforce interventions that facilitate increased access to
ECP in low-income and middle-income countries, reveal-
ing that in these countries too, provider knowledge
gaps, less than favourable attitudes and practice issues
impact access to ECP. The review also highlighted the
need to further examine provider performance to
inform the development of appropriate workforce
interventions.21
We therefore recommend that a formal analysis is
required to understand how services such as community
pharmacy should be reoriented to ensure they meet the
sexual and reproductive health needs of women in
Australia. Hence, in-depth interview with key stake-
holders—women and pharmacists—is the proposed
method to undertake the barriers analysis in this
Australian-based study that we have named ACCESS
(ACcessing Contraception for Emergency Supply Study).
In-depth interviewing will be used to develop an under-
standing of both individual (attitudinal, knowledge-
based, skills-related, risk assessment) and organisational
barriers and facilitators. Key informant interviews with
pharmacists as well as key informant interviews with
women living in Australia will be conducted over a
4-month period. The interview questions have been
developed based on the Theoretical Domains
Framework (TDF)22 and seek information pertaining to
women’s interactions with pharmacists when obtaining
the ECP, attitudes and beliefs of pharmacists and
women, as well as characteristics of those interviewed
(gender, age, highest education level, country of birth,
primary language spoken, place of residence, employ-
ment status, type of health insurance, marital status and
other relevant characteristics).
The major signiﬁcance of ACCESS will be the evi-
dence that it will provide to help inform workforce inter-
ventions in community pharmacy that will address
barriers to ECP access, promote increased adherence
with the PSA national guideline and therefore increase
supply of, and enhance access to, the ECP by women. A
key focus of the study is to evaluate practice against
national guideline evidence in order to facilitate ECP
supply. The data from this study will be used to develop
and pilot evidence-based interventions that will
strengthen the capacity of pharmacists to play a more
effective role in reducing unwanted pregnancies and the
abortion rate in Australia.
METHODS AND ANALYSIS
Design
Exploratory qualitative study.
Scope
The study will be carried out in collaboration with 10
pharmacy sites located in Victoria, Australia. We will
work with our partners to include pharmacies from
various different locations/regions within Victoria as
well as pharmacists from differing religious afﬁliations
and genders. The pharmacist interview will take place at
the pharmacy where they work and the women intervie-
wees will be asked to nominate a mutually agreeable
place such as the Monash University Parkville campus
where the chief investigator is based or over the phone.
The study will be carried out over a period of 12 months
where after gaining ethics approval, 3 months will be
designated for recruitment and 4 months towards con-
ducting the interviews which will be followed by a few
months of data analysis.
Sample size
The sample size of pharmacists we seek to interview is
anywhere between 10 and 50 participants. The sample
size of women participants we seek to interview is
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anywhere between 20 and 70 participants. The reason
for such a wide range in sample size is due to the fact
that since this is an exploratory qualitative study, the
number of interviews is dependent on whether satur-
ation of themes is reached and is dictated by resources.
Tool
Participants will be interviewed for between 30 min and
1½ h, and they will be asked open-ended questions
focusing on the barriers and facilitators to accessing
ECP from community pharmacies. The interview ques-
tions were formulated based on Michie’s TDF22 23
described in detail below.
Pharmacists will be encouraged to talk about internal
beliefs and attitudes that may hinder them from freely
providing the ECP. The 21 interview questions explore
the following 10 behavioural constructs in order to
assess pharmacist-related barriers to ECP provision:
knowledge; skills; social/professional role and identity;
beliefs about capabilities; memory, attention and deci-
sion processes; beliefs about consequences; behavioural
regulation; social inﬂuences; environmental context and
resources; and nature of behaviour (table 1).
Women will be encouraged to talk about the social
pressures, judgements and prior experiences that may
hinder them from accessing the ECP from pharmacies.
The 14 interview questions regarding consumer-related
barriers to ECP provision explore all the same behav-
ioural constructs mentioned above except for one:
memory, attention and decision processes (table 2).
Theoretical Domains Framework
Behaviour change is a key to increasing the uptake of
evidence into healthcare practice and improving health
outcomes. A variety of psychological theories have been
used to explain healthcare professional behaviours and
cognitions across a range of behaviours and settings.
However, the large number of theories and overlapping
Table 1 Interview guide for pharmacists according to Michie’s theoretical domains
Theoretical domains Interview prompts
Knowledge Are you aware of the PSA guideline for providing the ECP?
What is your understanding of this guideline?
Skills Have you had any training to use the PSA guideline? What kind of training?
What skills are required to supply ECP to someone? Are there any specific areas of
difficulty?
Social/professional role and
identity
Why do you provide the ECP in your pharmacy?
What are your views about the PSA guideline in general? Do you think it is an appropriate
part of your role to be following this guideline?
Does your ethical position affect your practice with regard to the ECP? How do you
reconcile this with your duty of care?
Beliefs about capabilities Do you find it difficult to apply the information in the PSA guideline to assess whether
someone should receive the ECP? What problems have you encountered? What would
help you to overcome these problems?
Do you think you have the skills to provide the ECP?
Do you fear that you might miss something when assessing whether someone should
receive the ECP?
Memory, attention and decision
processes
What thought processes might guide your decision to provide the ECP to someone?
Beliefs about consequences In your experience of providing the ECP, have you come across problems in your
population?
What do you think about the evidence behind the ECP?
Are there any advantages or disadvantages in trying to access the ECP via a pharmacy
instead of a health clinic or doctor?
Behavioural regulation Are there any procedures or ways of working that encourage or discourage you to provide
the ECP?
Social influences To what extent do social influences of peers, managers, etc, facilitate or hinder you in…
Providing the ECP?
Applying the PSA guideline?
Environmental context and
resources
Are there any environmental or resource factors that facilitate or hinder you in…
Providing the ECP?
Applying the PSA guideline?
Does your pharmacy use any checklists or tools when providing the ECP?
Nature of the behaviours What do pharmacies have to do differently to…
Improve awareness and access of the ECP?
Increase the application of the PSA guideline?
ECP, emergency contraceptive pill; PSA, Pharmaceutical Society of Australia.
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constructs presents a challenge for knowing how to
select and apply theories when exploring speciﬁc beha-
viours. The TDF, which includes constructs from 33
behaviour change theories, was developed to make the-
ories more accessible for implementation research-
ers.23 24 TDF consists of 14 theoretical domains and
exemplar questions for each to use in interviews or
focus groups to provide a comprehensive theoretical
assessment of implementation problems. This framework
has been used by research teams across several health-
care systems to explain implementation problems and
inform implementation interventions. The TDF has
proved useful across a number of healthcare systems and
for stronger explanatory and predictive power, and
therefore increased usefulness in informing interven-
tions to improve implementation and bring about other
behaviour change.23
In a brief review to assess the extent of TDF-based
research, 133 papers that cite the framework were identi-
ﬁed.23 Of these, 17 used the TDF as the basis for empir-
ical studies to explore health professionals’ behaviour.
The identiﬁed papers provide evidence of the impact of
the TDF on implementation research. Two major
strengths of the framework are its theoretical coverage
and its capacity to elicit beliefs that could signify key
mediators of behaviour change. The TDF has been
applied in many implementation studies.22 Speciﬁcally,
qualitative studies have concluded that the TDF was
useful for the comprehensive exploration of possible
explanations for suboptimal implementation behaviour
and for the identiﬁcation of suitable theories to further
investigate those behaviours.25 Another study document-
ing the development and use of the TDF stated that the
TDF is arguably the most comprehensive framework for
designing implementation interventions as it offers a
broad coverage of potential change pathways.26 An
example of a study utilising TDF to inform the design of
its intervention is the Healthy Kids Check (HKC). The
authors of this study concluded that TDF was able to
classify which barriers needed to be targeted to improve
implementation of HKC services.27 The study reported
here aims to do the same by using the TDF to identify
those behavioural constructs that will need to be tar-
geted in order to increase pharmacy performance in
ECP provision and ultimately women’s access to the ECP.
Recruitment
The pharmacy organisations involved in this research—
Australian Pharmaceutical Industry (API)/Priceline
Pharmacy Group whose main clientele are women and
Quality Pharmacy Group (QPG) who is focused on pro-
fessional service delivery—will nominate ﬁve pharmacies
each in their group as the sampling frame, that is, total
of 10 pharmacies in Victoria.
Every pharmacist working at the nominated pharma-
cies of both pharmacy groups will be given an informa-
tion pack by their organisation that will contain
information about the study. Pharmacists interested in
participating in the study will contact the researchers to
enrol in the study.
Women participants will be recruited by API/Priceline
Pharmacy Group by advertising the study in an in-store
Table 2 Interview guide for women according to Michie’s theoretical domains
Theoretical domains Interview prompts
Knowledge What is the ECP?
How long after unprotected sex can you take the ECP?
Where would you get the ECP from?
Did you know the ECP is available without a prescription from a pharmacy?
Skills Have you ever taken the ECP? From where? When?
(Note: if they got it from pharmacy—then the question is complete. If they got it from
somewhere else, and didn’t know about pharmacy access—then ask would they if they
could?)
Beliefs about capabilities What can be done to increase someone’s capability to access the ECP from a pharmacy?
Beliefs about consequences Are there any advantages or disadvantages in trying to access the ECP via a pharmacy
instead of a health clinic or doctor?
Behavioural regulation We want women to know that it is easy, convenient and fast to get the ECP from pharmacies.
What factors are important to you if you had to get the ECP from a pharmacy?
(Prompt: good factors include convenient location, fast service, avoidance of doctor’s visit
and so on; bad factors include lack of privacy, fear of judgement and so on)
Social/professional role and
identity
What skills do you think a pharmacist should have when providing the ECP?
Who do you think has the skills to provide the ECP?
Environmental context and
resources
Is there anything about the pharmacy environment that concerns you?
What information do you think a pharmacist should be able to provide you with?
Social influences Do you know people who have accessed the ECP from a pharmacy? What problems did they
encounter? Have their experiences facilitated or hindered you in accessing the ECP?
Nature of the behaviours What do pharmacies have to do differently to improve awareness of and access to the ECP?
ECP, emergency contraceptive pill.
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leaﬂet that will be provided to consumers (eg, placed in
store bags, placed on counters for consumers to self-
select). QPG will select women participants from their
database of approximately 70 000 pharmacy consumers.
This database contains both demographic and
medication-related information, that is, prescription and
non-prescription medicines purchased by consumers.
Additional recruitment methods will be employed if
recruiting women participants through the two phar-
macy groups aforementioned generates a low
response. These additional recruitment strategies will
be carried out by the Policy and Health Promotion
Manager from Women’s Health Victoria and the
Marketing and Communications Director from Marie
Stopes International (partner institutions). Women’s
Health Victoria will recruit through their networks
statewide by sending the recruitment ﬂyer to all the
managers and staff in their network of Victorian
Women’s Health Programs and School Nursing
Programs. Marie Stopes International will aid in
recruitment by posting the recruitment ﬂyer on the
‘Morning After Pill’ webpage on the Marie Stopes
International website. Lastly, Fernwood ﬁtness clubs,
which have exclusively female membership, will be
approached to aid in recruitment by displaying the
recruitment ﬂyer at selected locations in the gym such
as the reception area and women’s changing rooms.
Fernwood ﬁtness managers will be incentivised with a
$75 voucher for recruiting at least four women
participants.
The research assistant (AG, MPH, female, has experi-
ence in conducting and analysing interviews) will
contact women who are selected for the study after they
have been screened for the inclusion/exclusion criteria,
to determine the date, time and interview location that
suits them. Similarly, pharmacists selected for the study
will also be contacted in order to determine a suitable
date and time for the interview. No prior knowledge or
characteristics about the research assistant will be shared
with the participants, or relationship with her will be
established, prior to the interviews.
Inclusion criteria
In order to participate in the study, pharmacists should
be over the age of 18 and English should be their
primary language. The women participating in the study
should be between the ages 15 and 44 and English
should also be their primary language.
Exclusion criteria
Pharmacists who have never refused supply of the ECP
will be excluded from the study. The reason we included
this criterion is because the majority of our interview
questions aim at eliciting answers to situations where a
pharmacist has refused ECP access. In addition, women
who have not tried to access the ECP within the past
year will be excluded from the study. This is because we
want our participants to be able to describe in detail
(with minimal recall bias) their prior experience of
accessing the ECP.
Compensation
A $75 gift voucher will be given to pharmacist and
women interviewees.
Data analysis
All interviews will be tape-recorded and conducted by
the research assistant who does not intend to make ﬁeld
notes during or after. No one else besides the research
assistant and interviewee will be present and repeat
interviews will not be conducted. Interview data will be
transcribed. Participants will receive a copy of their tran-
script for approval. Data from the interviews will be
de-identiﬁed, so that no participant names or other
identifying features will appear in any form of data
reporting. Instead, codes will be used to identify who
the comment or quote was made by in the interview.
Transcripts will be read and coded by the research assist-
ant, then checked by the chief investigator and one
other investigator. The coding process will be deductive
with the selected theoretical domains as an organising
framework. If the codes validate the TDF domains, they
will be used to inform appropriate workforce interven-
tions for a pilot randomised controlled trial in selected
API/Priceline and QPG community pharmacies.
NVivo (V.10) will be used to manage data and code
these data into TDF domains. Data will be retained in
the Centre for Medicine Use and Safety at Monash
University, Parkville, for at least 5 years. Hard copies of
data will be kept in a locked ﬁling cabinet, in a locked
room at the Centre. All electronic data will be stored in
password-protected computers. Only the study team will
have access to the data.
Possible outcome of the analysis and benefits of the study
A study on barriers and facilitators to accessing the ECP
from community pharmacy in Australia has never been
undertaken before. We hope the data from this study
will help develop evidence-based workforce interven-
tions to strengthen the capacity and performance of
community pharmacists as key ECP providers.
Possible beneﬁts are that the study will contribute new
knowledge to the limited literature on barriers to ECP
access in the Australian context and will help inform the
development of evidence-based interventions in commu-
nity pharmacy that will achieve the following: address
barriers to ECP access, promote increased adherence
with a national practice guideline for pharmacists that
benchmarks best practice in the area, and therefore
increase the supply of, and enhance access to, the ECP
by women.
ETHICS AND DISSEMINATION
Participants will be assured of their anonymity and that
the primary purpose of the research is to identify the
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barriers and facilitators to accessing the ECP from com-
munity pharmacies in Australia.
Written informed consent will be taken from all phar-
macists and women interviewed. All study participants
will be provided with an explanatory statement contain-
ing information about the study, what participation
involves and the contact details of the Monash
University Ethics Committee, so that they are able to
report any concerns or complaints about the study. All
respondents have the right to refuse to answer any ques-
tion posed by the interviewer, and can withdraw from
the study prior to having approved the interview
transcript.
The risk of physical or psychological harms from par-
ticipation in the study will be negligible. The study only
involves interviews with participants; however, given the
potentially sensitive nature of the topic, the questions in
both have been designed to be as objective as possible
and have been worded carefully. Participants will not be
identiﬁed by name in any report or publication resulting
from the study data. There are no risks for the
researchers.
The results from the study will be disseminated to all
researchers and organisational partners associated with
this study, who will brainstorm ideas for interventions
that would address barriers and facilitators to access
identiﬁed from the interviews. The study participants
will receive an executive summary of the research ﬁnd-
ings. In addition, the ﬁndings will be written up for pub-
lication in peer-reviewed journals in specialist, general,
national or international journals.
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